Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

ClinicalTrials.gov ID: NCT05703971

Public ClinicalTrials.gov record NCT05703971. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Study identification

NCT ID
NCT05703971
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Genprex, Inc.
Industry
Enrollment
62 participants

Conditions and interventions

Interventions

  • quaratusugene ozeplasmid Biological
  • atezolizumab Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 8, 2024
Primary completion
May 31, 2026
Completion
Jul 31, 2027
Last update posted
Jun 2, 2026

2024 – 2027

United States locations

U.S. sites
17
U.S. states
7
U.S. cities
12
Facility City State ZIP Site status
Rocky Mountain Cancer Centers, LLP Lone Tree Colorado 80124 Recruiting
Washington University School of Medicine - Siteman Cancer Center St Louis Missouri 63110 Recruiting
Gabrail Cancer Center Research Canton Ohio 44718 Recruiting
Oncology_Hematology Care Clinical Trials, LLC Cincinnati Ohio 45211 Recruiting
Oncology_Hematology Care Clinical Trials, LLC Cincinnati Ohio 45236 Recruiting
Oncology_Hematology Care Clinical Trials, LLC Cincinnati Ohio 45242 Recruiting
Oncology_Hematology Care Clinical Trials, LLC Cincinnati Ohio 45245 Recruiting
Oncology_Hematology Care Clinical Trials, LLC Fairfield Ohio 45014 Recruiting
Willamette Valley Cancer Institute (Oregon) Eugene Oregon 97401 Recruiting
Northwest Cancer Specialists, P.C. Portland Oregon 97213-2982 Recruiting
Providence Cancer Institute Portland Oregon 97213 Recruiting
Northwest Cancer Specialists, P.C. Portland Oregon 97227 Recruiting
Northwest Cancer Specialists, P.C. Tigard Oregon 97223 Recruiting
Texas Oncology - DFW Dallas Texas 75246 Recruiting
Texas Oncology - Northeast Texas Tyler Texas 75702 Recruiting
Virginia Cancer Specialists, PC Fairfax Virginia 22031 Recruiting
Northwest Cancer Specialists, P.C. Vancouver Washington 98684 Terminated

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05703971, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 2, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05703971 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →